BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol 2017;198:530-7. [PMID: 28411072 DOI: 10.1016/j.juro.2017.04.067] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Bersanelli M, Rebuzzi SE, Roviello G, Catalano M, Brunelli M, Rizzo M. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma. Hum Vaccin Immunother 2023;19:2171672. [PMID: 36758960 DOI: 10.1080/21645515.2023.2171672] [Reference Citation Analysis]
2 Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 2023:S2405-4569(23)00048-2. [PMID: 36863962 DOI: 10.1016/j.euf.2023.02.008] [Reference Citation Analysis]
3 Climent C, Soriano S, Bonfill T, Lopez N, Rodriguez M, Sierra M, Andreu P, Fragio M, Busquets M, Carrasco A, Cano O, Seguí MA, Gallardo E. The role of immunotherapy in non-clear cell renal cell carcinoma. Front Oncol 2023;13:941835. [PMID: 36816976 DOI: 10.3389/fonc.2023.941835] [Reference Citation Analysis]
4 Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer 2023;21:63-8. [PMID: 36517393 DOI: 10.1016/j.clgc.2022.11.015] [Reference Citation Analysis]
5 杨 桂. One Case Report of Sarcomatoid Renal Cell Carcinoma. ACM 2023;13:1906-1913. [DOI: 10.12677/acm.2023.132264] [Reference Citation Analysis]
6 Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022;10. [PMID: 36549781 DOI: 10.1136/jitc-2022-005445] [Reference Citation Analysis]
7 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
8 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
9 Takeuchi M, Froemming AT, Kawashima A, Thapa P, Carter RE, Cheville JC, Thompson RH, Takahashi N. Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation. Abdom Radiol (NY) 2022;47:2168-77. [PMID: 35381868 DOI: 10.1007/s00261-022-03501-9] [Reference Citation Analysis]
10 Al-juhaishi T, Deng X, Bandyopadhyay D, Paul A. The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis. Cureus 2022. [DOI: 10.7759/cureus.25395] [Reference Citation Analysis]
11 Zhang Y, Hu J, Yang J, Xie Y, Chen Z, Shangguan W, Han J, He W, Yang J, Zheng Z, Zhong Q, Zhu D, Xie W. Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database. Front Oncol 2022;12:814512. [PMID: 35127544 DOI: 10.3389/fonc.2022.814512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
13 Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy 2021. [PMID: 34806404 DOI: 10.2217/imt-2021-0157] [Reference Citation Analysis]
14 Nwabundo A, Damilola G, Olabisi AO, Ishmael J. Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma. J Kidney Cancer VHL 2021;8:38-42. [PMID: 34765405 DOI: 10.15586/jkcvhl.v8i4.168] [Reference Citation Analysis]
15 Martini DJ, Kline MR, Liu Y, Shabto JM, Carthon BC, Russler GA, Yantorni L, Hitron EE, Caulfield S, Goldman JM, Harris WB, Kucuk O, Master VA, Bilen MA. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat Res Commun 2021;28:100393. [PMID: 34029879 DOI: 10.1016/j.ctarc.2021.100393] [Reference Citation Analysis]
16 Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist 2021;26:476-82. [PMID: 33792094 DOI: 10.1002/onco.13770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
17 Tachibana H, Kondo T, Ishihara H, Fukuda H, Yoshida K, Takagi T, Izuka J, Kobayashi H, Tanabe K. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. Jpn J Clin Oncol 2021;51:646-53. [PMID: 33212488 DOI: 10.1093/jjco/hyaa229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
18 Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Khan Y, Slattery TD, Pickering LM. Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers (Basel) 2020;12:E3750. [PMID: 33322163 DOI: 10.3390/cancers12123750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 2021;19:103-16. [PMID: 33358151 DOI: 10.1016/j.clgc.2020.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
21 Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 2021;39:134.e9-134.e16. [PMID: 33187886 DOI: 10.1016/j.urolonc.2020.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Carbone F, Huang JK, Perelli L, Poggetto ED, Gutschner T, Tomihara H, Soeung M, Lam TNA, Xia R, Zhu C, Song X, Zhang J, Sircar K, Malouf GG, Sgambato A, Karam JA, Gao J, Jonasch E, Viale A, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Msaouel P, Litchfield K, Turajlic S, Heffernan TP, Chen YB, Dinatale RG, Hakimi AA, Bristow CA, Tannir NM, Carugo A, Genovese G. 9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas.. [DOI: 10.1101/2020.11.03.367433] [Reference Citation Analysis]
23 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
24 Gan CL, Dudani S, Heng DYC. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. Cancer J 2020;26:365-75. [PMID: 32947304 DOI: 10.1097/PPO.0000000000000468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Eraslan E, Yalçintaş Ü. Long-term follow-up results of patients with sarcomatoid RCC: A retrospective evaluation of a single center experience. Journal of Surgery and Medicine 2020;4:803-807. [DOI: 10.28982/josam.789516] [Reference Citation Analysis]
26 Ji B, Li D, Fu S, Zhang Z, Yang T, Wu Y, Zuo Y, Xu Z, Yu N. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database. Med Sci Monit 2020;26:e921297. [PMID: 32516796 DOI: 10.12659/MSM.921297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun 2020;23:100172. [PMID: 32252014 DOI: 10.1016/j.ctarc.2020.100172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
28 Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol 2020;20:14. [PMID: 32070319 DOI: 10.1186/s12894-020-0584-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
29 Ross JA, Msaouel P, Tannir NM. Management of Non-Clear Cell Renal Cell Carcinoma. Renal Cancer 2020. [DOI: 10.1007/978-3-030-24378-4_18] [Reference Citation Analysis]
30 Wang YS, Shuang WB, Yin KQ, Tong XN, Xia MC, Yang HS. Analysis of the factors influencing the survival time of patients with sarcomatoid renal cell carcinoma. Mol Clin Oncol 2019;11:405-10. [PMID: 31475069 DOI: 10.3892/mco.2019.1900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Kondisetty G, Borkar PV, Kondisetty S, Thomas A. Retrospective review of experience with sarcomatoid renal cell carcinoma: Multimodality treatment remains an unmet goal. Urol Ann 2019;11:385-8. [PMID: 31649458 DOI: 10.4103/UA.UA_106_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Arora K, Psutka SP. Posttreatment Surveillance for Renal Cell Carcinoma. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_16] [Reference Citation Analysis]
33 Wang Z, Zeng X, Chen R, Chen Z. Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Manag Res 2018;10:5339-47. [PMID: 30464630 DOI: 10.2147/CMAR.S176242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 El Mouallem N, Smith SC, Paul AK. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor. J Oncol Pract 2018;14:511-3. [PMID: 29920137 DOI: 10.1200/JOP.18.00213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
35 Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
36 Rashid S, Akhtar M. Sarcomatoid Variant of Urothelial Carcinoma of the Renal Pelvis with Inferior Vena Cava Tumour Thrombus: A Case Report and Literature Review. Case Rep Pathol 2018;2018:1837510. [PMID: 29581908 DOI: 10.1155/2018/1837510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol 2018;36:265-71. [PMID: 29306556 DOI: 10.1016/j.urolonc.2017.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
38 Edelson MP, Wu WJ, Kurzyna A, Steckel J. Rapid recurrence and radiographic progression of sarcomatoid renal cell carcinoma. Urol Case Rep 2018;16:6-8. [PMID: 29034177 DOI: 10.1016/j.eucr.2017.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Smith JA. This Month in Adult Urology. Journal of Urology 2017;198:453-455. [DOI: 10.1016/j.juro.2017.06.021] [Reference Citation Analysis]
40 Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer 2017;83:237-46. [PMID: 28756136 DOI: 10.1016/j.ejca.2017.06.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]